NVCT

Nuvectis Pharma Inc

NASDAQ: NVCT · HEALTHCARE · BIOTECHNOLOGY

$11.06

+3.87% today

Updated 2026-06-04

Market cap

$256.50M

P/E ratio

—

P/S ratio

—

EPS (TTM)

$-1.31

Dividend yield

—

52W range

$6 – $13

Volume

0.1M

Market cap

$256.50M

P/E ratio

—

P/S ratio

—

EPS (TTM)

$-1.31

Dividend yield

—

52W range

$6 – $13

Volume

0.1M

WallStSmart proprietary scores

out of 100

Grade: F

Strong Sell

Investment rating

4.3

Growth

5.5

Quality

C+

3.0

Profitability

5.0

Valuation

C+

3/9

Piotroski F-Score

Weak

—

Altman Z-Score

—

Industry rank

—

View all highly rated stocks (75+) →199 stocks currently score above 75

Price targets

Analyst target

$16.80

+51.90%

12-Month target

—

Intrinsic (DCF)

—

Margin of safety

—

2 Strong Buy3 Buy0 Hold0 Sell0 Strong Sell

Price chart

Stock snapshot

Strengths

Insufficient data

Risks

- Piotroski 3/9 — weak financial health

- Thin margins at 0.00%

- Negative free cash flow $-6.51M

Key financials

Revenue Net Income Free Cash Flow

Metric	2022	2023	2024	2025	TTM
Revenue	$149000.00	$0.00	$0.00	$0.00	$0.00
Net income	$-18.79M	$-22.26M	$-19.00M	$-26.44M	$-6.05M
EPS	—	—	—	—	$-1.31
Free cash flow	$-13.56M	$-15.95M	$-12.25M	$-16.01M	$-6.51M
Profit margin	-12,608.72%	—	—	—	—

Recent insider activity

Date	Insider	Type	Shares	Price
2026-01-06	SHEMESH, SHAY	Buy	150,000	—
2026-01-06	PORADOSU, ENRIQUE	Buy	150,000	—
2026-01-06	CARSON, MICHAEL J.	Buy	61,200	—

Peer comparison

Company	Mkt Cap	Score	Growth	Profit	Value	Quality	MoS	Rating
NVCT	$256.50M	17	4.3	3.0	5.0	5.5	—	Avoid
LLY	$1.01T	76	10.0	10.0	4.3	6.0	—	Strong Buy
JNJ	$567.28B	57	4.7	9.0	3.3	6.0	-67.79%	Buy
ABBV	$391.50B	63	4.0	8.0	4.0	5.0	-48.06%	Buy
UNH	$373.28B	54	5.3	5.5	4.0	5.5	-26.94%	Buy
NVS	$289.19B	49	3.3	9.0	3.3	4.5	-65.15%	Hold

Smart narrative

Nuvectis Pharma Inc trades at $11.06. Our Smart Value Score of 17/100 indicates the stock is weak. The company scores 3/9 on the Piotroski F-Score.

Frequently asked questions

What is Nuvectis Pharma Inc's stock price?

Nuvectis Pharma Inc (NVCT) trades at $11.06.

Is Nuvectis Pharma Inc overvalued?

Nuvectis Pharma Inc carries a Smart Value Score of 17/100 (Grade F), which we rate Strong Sell. That score blends growth, quality, and valuation into one read.

What is the price target of Nuvectis Pharma Inc (NVCT)?

The 12-month analyst consensus target is $16.80, about 51.9% above the current $11.06. A consensus target is the average of Wall Street's 12-month forecasts, so it works as a sentiment gauge rather than a guarantee, and it resets with every earnings cycle.

Company info

SectorHEALTHCARE

IndustryBIOTECHNOLOGY

CountryUSA

ExchangeNASDAQ

CurrencyUSD

Quick metrics

P/S ratio—

ROE-154.40%

Beta-0.07

50D MA$9.21

200D MA$7.75

Shares out0.03B

Float0.02B

Short ratio—

Avg volume0.1M

Performance

1 week—

1 month—

3 months—

YTD—

1 year—

3 years—

5 years—

Compare

NVCT vs LLY →NVCT vs JNJ →NVCT vs ABBV →Stock screener →